tbuckley/cabot-search huggingface dataset:
Abstract 4465: Inhibition of tumor growth, lymphangiogenesis, and metastasis by iron chelators, deferoxamine and deferasirox, in breast cancers
Authors: Han Na Kang, Myoung Hee Kang, Jung Lim Km, Jun Suk Kim, Chul Won Choi, Jea Hong Seo, Young A Yoo
Journal: Cancer Research (2011)

Abstract Iron participates in a range of reactions that are necessary for cell viability and cell proliferation and it has been reported that iron depletion by chelator inhibits the proliferation of various cancer cells. Among the different kind of iron chelators, deferoxamine is the most widely studied molecule as an anti-tumor agent. Deferasirox is a new rationally-designed oral iron chelator and there are few reports regarding in vitro and in vivo effect on myeloid leukemia cells.This study was undertaken to evaluate the in vitro and in vivo effects of DFX (deferoxamine) and DFS (Deferasirox) on anti-cancer activities in breast cancer cells and to define molecular mechanisms underlying these effects. We found that DFX or DFS displayed significant anti-proliferative activity in a dose-and time-dependent manner in MDA-MB-231 and MDA-MB-435 cells. DFX or DFS treatment led to the enhanced percentages of apoptotic cell, which was mediated through the mitochondrial death pathway that requires up-regulation of Bad phosphorylation, PUMA, and caspase-3 /-9 activities. In addition, DFX or DFS treatment significantly attenuated the motility and invasiveness of metastatic breast cancer cells, which is attributed to the decrease in EMT process and lymphangiogenesis. Importantly, the in vivo study revealed that DFX or DFS retarded tumor growth and suppressed the metastatic capacity to lymph nodes by down-regulating lymphangiogenesis in the orthotropic breast tumor model. These data demonstrate that DFX or DFS induces anti-cancer activity of breast cancer cells by both inducing apoptosis and suppressing metastasis in vitro and in vivo. Hence, DFX and DFS could provide another strategy for treating breast cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4465. doi:10.1158/1538-7445.AM2011-4465
SAT0317 Baseline MRA Predicts the Treatment Response to Vasodilator Udenafil in Patients with Secondary Raynaud's Phenomenon
Authors: J.K. Park, J. Moon, E.Y. Lee, Y.W. Song, E.B. Lee, E.-A. Park
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> High-resolution MR angiography (HR-MRA) demonstrates blood flow in the digital arteries, which correlates with the severity of Raynaud9s phenomenon (RP) <h3>Objectives</h3> This study investigates whether baseline HR-MRA of the hand can predict the treatment response to udenafil, a new PDE5-inhibitor, in patients with secondary RP. <h3>Methods</h3> Baseline MRA and Doppler ultrasound were obtained in 12 patients with secondary RP. The patients were treated with udenafil 100 mg/day for 4 weeks and changes in blood flow were measured. Blood flow on MRA was scored on a 4-point scale: 0, no visible flow; 1, visible flow to the proximal phalanx; 2, to the middle phalanx; and 3, to the distal phalanx. Peak systolic velocity (PSV) was measured to determine blood flow. Paired t-test and ANOVA were used to determine the treatment response of the different MRA scores. Trial registration: [www.clinicaltrials.gov, protocol number NCT01280266]. <h3>Results</h3> On baseline MRA, 53.3% of digital arteries had an MRA score of 0, 25.8% MRA score of 1, 9.2% MRA score of 2, and 11.6% MRA score of 3. Overall, 4-week udenafil treatment improved digital flow (P&lt;0.05) in all MRA scores. Digital arteries with MRA score 2 showed the best response with improvement in PSV by 14.5 mm/sec (P&lt;0.01), whereas improvement in arteries of MRA scores 1 and 3 were not better than MRA scores of 0 (all, P&gt;0.05). <h3>Conclusions</h3> Digital arteries with moderate blood flow observed on MRA respond best to treatment with udenalfil. Therefore, baseline MRA may help predict treatment response in patients with secondary RP. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2186
Jejunal gastrointestinal stromal tumor missed by three capsule endoscopies
Authors: G. Mavrogenis, D. Coumaros, C. Renard, J.-P. Bellocq, D. Defta, D. Charneau, J. Leroy
Journal: Endoscopy (2011)

We read with interest the case report by Jovanovic et al. about the ineffectiveness of capsule endoscopy and total double-balloon enteroscopy (DBE) to elicit the cause of obscure overt gastrointestinal bleeding in a case of gastrointestinal stromal tumor (GIST) [1].
Braf Mutation in Colon Cancer Patients with Microsatellite Instability (Msi): a Monoinstitutional Analysis
Authors: Michela Frisinghelli, Antonello Veccia, Barbara Soini, Sonia Brugnara, Lucianna Maria Russo, Mattia Barbareschi, Roberto Togni, Salvatore Girlando, Enzo Galligioni
Journal: Annals of Oncology (2013)
Persistence of isolated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse – a European pooled analysis.
Authors: B Naume, T Fehm, G Wiedswang, J Jückstock, E Borgen, B Rack, M Synnestvedt, S Braun, H Sommer, E Solomayer, K Pantel, K Friese, W Janni
Journal: Cancer Research (2009)

Abstract Abstract #304 Purpose:&amp;#x2028; The prognostic significance of DTC in the BM of breast cancer pts at the time of primary diagnosis has already been confirmed by a large pooled analysis. In view of the lack of early indicators for secondary adjuvant treatment, we here evaluated whether the persistence of DTC after adjuvant therapy confers a risk for relapse and breast cancer-related death.&amp;#x2028; Patients and Methods:&amp;#x2028; We analyzed BM aspirates of 723 pts from academic breast cancer units in Oslo (n=356), Munich (n=228) and Tuebingen (n=139) during recurrence-free follow-up at a mean interval of 31.7 months (standard deviation [std] 19.4 months) after primary diagnosis of breast cancer pT1-4, pN0-3 pM0. Carcinoma cells were detected using a standardized immunoassay with the monoclonal antibodies A45-B/B3 (Munich, Tuebingen), or AE1 and AE3 (Oslo), directed against cytokeratin (CK). Pts were followed for a median of 54.5 months (SD 25.1 months) after primary diagnosis.&amp;#x2028; Results:&amp;#x2028; Persistent DTC in the BM was detected in 15.5% of the pts (n=112). The Kaplan-Meier estimate for mean distant relapse-free survival was 162.5 months (157.9 – 167.0 95%CI) in pts with negative and 102.4 months (94.2 – 110.6, 95% CI, p&amp;lt; .0001, log rank test) in pts with positive BM status. The mean overall survival was 170.1 months, (167.7 – 172.5 95% CI), compared to 113.4 months in patients with persistent DTC in BM (107.3 – 119.5, p &amp;lt; .0001). In multivariate Cox regression analysis, allowing for BM status, tumor size, nodal status and histopathological grading, presence of DTC was an independent prognostic factor for reduced breast cancer specific survival ((RR 3.42, 1.64 – 7.13 95% CI, p= .001).&amp;#x2028; Conclusion:&amp;#x2028; Persistent DTC significantly predicts an increased risk for subsequent relapse, and, therefore, might serve as a potent monitoring tool for the follow-up of breast cancer pts. Future therapeutic intervention trials are currently being initiated to assess the benefit of secondary adjuvant treatment based on DTC detection as stratification parameter. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 304.
A genomic case study of mixed fibrolamellar hepatocellular carcinoma
Authors: O.L. Griffith, M. Griffith, K. Krysiak, V. Magrini, A. Ramu, Z.L. Skidmore, J. Kunisaki, R. Austin, S. McGrath, J. Zhang, R. Demeter, T. Graves, J.M. Eldred, J. Walker, D.E. Larson, C.A. Maher, Y. Lin, W. Chapman, A. Mahadevan, R. Miksad, I. Nasser, D.W. Hanto, E.R. Mardis
Journal: Annals of Oncology (2016)

Mixed fibrolamellar hepatocellular carcinoma (mFL-HCC) is a rare liver tumor defined by the presence of both pure FL-HCC and conventional HCC components, represents up to 25% of cases of FL-HCC, and has been associated with worse prognosis. Recent genomic characterization of pure FL-HCC identified a highly recurrent transcript fusion (DNAJB1:PRKACA) not found in conventional HCC.We performed exome and transcriptome sequencing of a case of mFL-HCC. A novel BAC-capture approach was developed to identify a 400 kb deletion as the underlying genomic mechanism for a DNAJB1:PRKACA fusion in this case. A sensitive Nanostring Elements assay was used to screen for this transcript fusion in a second case of mFL-HCC, 112 additional HCC samples and 44 adjacent non-tumor liver samples.We report the first comprehensive genomic analysis of a case of mFL-HCC. No common HCC-associated mutations were identified. The very low mutation rate of this case, large number of mostly single-copy, long-range copy number variants, and high expression of ERBB2 were more consistent with previous reports of pure FL-HCC than conventional HCC. In particular, the DNAJB1:PRKACA fusion transcript specifically associated with pure FL-HCC was detected at very high expression levels. Subsequent analysis revealed the presence of this fusion in all primary and metastatic samples, including those with mixed or conventional HCC pathology. A second case of mFL-HCC confirmed our finding that the fusion was detectable in conventional components. An expanded screen identified a third case of fusion-positive HCC, which upon review, also had both conventional and fibrolamellar features. This screen confirmed the absence of the fusion in all conventional HCC and adjacent non-tumor liver samples.These results indicate that mFL-HCC is similar to pure FL-HCC at the genomic level and the DNAJB1:PRKACA fusion can be used as a diagnostic tool for both pure and mFL-HCC.
P4-19-05: A Population-Based Study of Guideline-Based BRCA Screening in Male Breast Carcinoma.
Authors: KL Bradley, JE Nuk, SK Chia, D Villa, CH Speers, R Woods, S Young, S Tyldesley
Journal: Cancer Research (2011)

Abstract Purpose: The British Columbia Cancer Agency (BCCA) Hereditary Cancer Program (HCP) is a publicly funded, centralized program that provides BRCA testing to patients with male breast cancer (MBC) who meet specified referral criteria (aimed at detecting a mutation in &amp;gt; 10% of those tested). Criteria include: MBC with Ashkenazi heritage, MBC with one other family member with breast or ovarian cancer, MBC diagnosed at &amp;lt; 35 years, Bilateral MBC with first diagnosed at &amp;lt; 50 year. In this context, the purpose was to study referral patterns for hereditary counselling and outcomes of BRCA testing within a population-based study of male breast carcinoma. Patients and Methods Records of consecutive cases of invasive MBC diagnosed from 2000 to 2010 were reviewed. We documented any recorded personal and family history of cancer. For those meeting the HCP referral criteria we recorded whether a referral was made and the outcome of any genetic testing. Results: Of 158 cases of MBC, 23 (14.6%) patients (21 met referral criteria; 2 did not) were seen for genetic counselling, of whom 21 were offered BRCA1/2 testing, and 19 accepted testing. Of 19 patients with BRCA1/2 genetic test results, 3 (16%) had a pathogenic mutation identified; one in the BRCA1 gene (c.1387_1390delinsGAAAG) and two in the BRCA2 gene (***c.755_758delACAG; c.1813dupA). In a further 4 cases (21%) an unclassified variant in BRCA1 was identified. In the remaining 12 cases (63%), testing was uninformative. Conclusions: The BRCA1/2 mutation detection rate of 16% is in line with the expected rate of &amp;gt;10% using established selection criteria. Expanding the criteria at this time to include all male breast cancers would be expected to decrease the detection rate below 10% with the potential to negatively impact on the publicly-funded and finite resources of the Hereditary Cancer Program and Cancer Genetics Laboratory. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-19-05.
Abstract 3948: Proteome analysis of ovarian cancer cell lines under hypoxic conditon by two-dimensional difference gel electrophoresis (2D-DIGE)
Authors: Ryoko Kikuchi, Kei-ichi Iwaya, Osamu Matsubara
Journal: Cancer Research (2012)

Abstract The cancer cells which survived hypoxia are known to have aggressive properties and can easily metastasize to other regions, however, the molecular basis of hypoxia-induced changes of cancer cells is not clear. We used a proteomic approach to identify the hypoxia-responsive proteins in 3 ovarian cancer cell lines, KFr13, RMUG-S and ES-2. The cell lines were incubated under lower oxygen concentration (5%) and under normal oxygen concentration (20%) in 48 hours. Even in lower oxygen concentration, the cells survived and increased in number in these 48 hours. The total proteins from the cells were extracted and analysed by 2D-DIGE and MALDI-TOF-MS. We identified the protein, HRP1, whose molecular weight is 71KDa, that all 3 cell lines showed decreased expression under lower oxygen condition compared with normal condition. HRP1 secretion is a growth arrest signal for rat mammary adenocarcionma cells. HRP1 is one of the new candidates for hypoxia-related proteins in ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3948. doi:1538-7445.AM2012-3948
Venous Thromboembolism during Pregnancy
Authors: Marc R. Toglia, John G. Weg
Journal: New England Journal of Medicine (1996)

Venous thromboembolism is an uncommon but leading cause of illness and death during pregnancy and the puerperium.1,2 It has been reported to occur in 1 in 1000 to 1 in 2000 pregnancies,3,4 although few studies have used objective diagnostic techniques. Over the past two decades, there has been considerable change in the management of venous thromboembolism in nonpregnant patients. Moreover, our understanding of changes in the coagulation system during pregnancy has increased. However, the management of venous thromboembolism during pregnancy remains a subject of controversy because of the lack of prospective clinical trials. In this article, we will . . .
Differential Gene Expression Profiles in Breast Cancer Tumors from Young and Post-Menopausal Patients.
Authors: C. Moreira-Filho, P. Ramos, P. Ramos, L. Barreta, H. Brentani, B. Corradini, M. Maciel, D. Carraro, M. Achatz, R. Michelli, E. Lyra, S. Grosso, M. Folgueira, M. Katayama, M. Brentani
Journal: Cancer Research (2009)

Abstract Breast cancer in young patients (&amp;lt;35 yrs) has been hypothesized to be more histologically aggressive than those occurring in older cohorts, based mainly in their histopahtological features and worse prognosis. Our current knowledge of the genes involved in such differences is limited. To obtain insight into the molecular processes underlying tumorigenesis in young women we have used 44K cDNA microarrays (Agilent) to compare the gene expression profiles of 30 samples obtained from patients younger than 35 years (median 32,5, range 25-35) and 19 post-menopausal patients (median 66, range 55-88 ), all of them with ductal invasive carcinoma. Both age groups showed similar incidence of ER and PR-positive cases (70 and 60%, respectively). We considered as differentially expressed genes those presenting a p value below 0.01(t test) and fold variation of+/- 2.5.Gene ontology was performed using the GOTree machine tool (GOTM). By such criteria, 121 genes (86% down-regulated) were identified between the two groups here analyzed. In tumors arising in younger women we found an overrepresentation of genes involved with G-protein receptor signaling,cytoskeleton and muscle development, including ankyrin 3,filamin B, gfsarcoglycan and small proline- rich protein, one of the cornified-envelope structural precursor protein. In addition, solely in the younger women set we compared the gene profiles between women with (n =19) or without (n = 10) familial history of breast carcinoma. Using the same criteria, 59 transcripts distinguished the two subsets: GO categories over represented in tumors from patients with familial history included cell-cell adhesion, cytoskeleton organization,cell motility and protein binding related genes. These results indicate that breast cancer tumors arising in young women, besides their uniqueness regarding tumorigenesis, also differ among familial and non-familial cases as revealed by gene expression profiles.Support: FAPESP 04/14029-1 Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6138.
IMPACT OF MODERATE TO SEVERE RENAL IMPAIRMENT ON THE LONG-TERM CLINICAL OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION
Authors: Sung Woo Cho, Jin Kyung Hwang, Kwang Jin Chun, Seung-Jung Park, Kyoung-Min Park, June Soo Kim, Jiseok Kang, Kyunghee Lim, Young Keun On
Journal: Journal of the American College of Cardiology (2016)
Computerized Histologic Image-Based Risk Score (IbRiS) Classifier for ER+ Breast Cancer.
Authors: S. Ganesan, A. Madabhushi, A. Basavanhally, J. Xu, G. Bhanot, N. Barnard, D. Toppmeyer
Journal: Cancer Research (2009)

Abstract Background: Measurement of estrogen receptor (ER) expression is a routine part of clinical evaluation of individual breast cancers and is used to guide treatment. However not all ER+ breast cancers show equal benefit from hormonal or other treatment. The RT-PCR based Oncotype Dx assay, has been recently shown to robustly stratify early stage ER+ breast cancer and identify those tumors that will have low recurrence rates when treated with adjuvant hormonal therapy alone. Interestingly, standard pathologic grading, based on visual analysis of tumor morphology by trained pathologists, has a strong correlation with Oncotype Dx recurrence scores; low recurrence tumors are mostly low grade, and high recurrence tumors are mostly high grade. However, a major problem with use of pathologist-assigned histologic grade as a prognostic tool is the lack of reproducibility of histological grading between different pathologists. Computer aided image analysis and machine learning techniques offer a way to obtain highly reproducible image-based classification of ER+ breast cancer. These analyses can be performed on digital images of routinely obtained breast cancer histology and be incorporated into a prognostic assay.Materials and Methods: High resolution digital images were obtained for a series of ER+ breast cancers for which associated Oncotype Dx Assay results were available. Regions of invasive breast cancer were identified and then processed by computer-assisted image analysis methods. An automated nuclear detection scheme based on Expectation Maximization algorithm was used to identify cancer cell nuclei, followed by graph-based feature extraction using the Voronoi graph, Delaunay Triangulation and Minimum Spanning Trees, and dimensionality reduction using Graph Embedding with Support Vector Machine based classification. The final manifold generated by GE was unwrapped into a linear space and a Euclidean distance metric was used to generate a single score (Image Based Risk Score- (IbRiS)) for each sample. Correlations between IbRS, clinical features such as grade, and Oncotype Dx Recurrance Score were determined.Results: Unsupervised analysis of image-based features of high resolution digital images of ER+ breast cancer histology leads to natural separation of tumors, with low grade tumors separating from high grade tumors. There is also a robust separation of tumors with high Oncotype Dx Recurrance Scores from tumors with low Recurrance Scores.Discussion: Unsupervised analysis of high resolution image-based features can stratify ER+ breast cancers in a fashion that correlates well with a gene-expression based prognostic assay, Oncotype Dx. These data suggest that tumors with distinct gene-expression profiles also have distinct image-based features that can be measured by computer-aided image analysis and used to build prognostic and predictive assays. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3046.
MULTIMODALITY INTRAVASCULAR IMAGING TO PREDICT PERIPROCEDURAL MYOCARDIAL INFARCTION DURING PERCUTANEOUS CORONARY INTERVENTION
Authors: Annapoorna Subhash Kini, Sadako Motoyama, Yuliya Vengrenyuk, Jacobo Pena, Usman Baber, Arjun Bhat, Pedro Moreno, Jason Kovacic, Jagat Narula, Samin Sharma
Journal: Journal of the American College of Cardiology (2015)
Obesity — Its Possible Effect on College Acceptance
Authors: Helen Canning, Jean Mayer
Journal: New England Journal of Medicine (1966)

CASUAL observation had suggested to us that obesity was less prevalent in high-ranking, so called "prestige" colleges than in public high schools. We therefore decided to investigate whether or not obesity affected college acceptance. If it did, it would have important implications for public-health programs directed at obesity.We chose for our investigation an outstanding high-school system and an Ivy League and a Seven Sister college.§ Our results did, indeed, indicate that there was less obesity in the colleges than in the high schools. No differences were found in academic criteria and application rates between obese and nonobese high-school students. . . .
No more news from the cerebellum
Authors: Steven R. Vincent
Journal: Behavioral and Brain Sciences (1996)

Although a number of further studies have now been published exploring possible roles for the NO-cGMP signal transduction system in various models of LTD, there still appears to be confusion regarding the physiological functions of these molecules in the cerebellar cortex. What seems clear is that NO can be produced in granule cells and basket cells, and can stimulate soluble guanylyl cyclase, thereby activating cGMP-dependent protein ldnase in Purkinje cells. However, substrates for this Idnase are still poorly defined, and its role in the modulation of synaptic transmission remains to be determined. The recent development of novel transgenic models and new pharmacological agents with which to dissect this signal transduction system, gives one confidence that our understanding of the cerebellar NO system will quickly advance. With its unique properties as a signaling molecule, it is clear that NO news has been good news for those studying synaptic plasticity in the cerebellum.
TRIGLYCERIDES AND HDL CHOLESTEROL ARE ASSOCIATED WITH CORONARY ARTERY DISEASE PROGNOSIS AMONG STATIN TREATED PATIENTS UNDERDOING CORONARY CT ANGIOGRAPHY: PARTNERS HEALTHCARE CT REGISTRY
Authors: Edward A. Hulten, Marcio Bittencourt, Brian Ghoshhajra, Avinainder Singh, Suhny Abbara, Khurram Nasir, Michael Blaha, Udo Hoffmann, Marcelo Di Carli, Ron Blankstein
Journal: Journal of the American College of Cardiology (2015)